NEW YORK — In a landmarktherapeutic advancement, researchers have disseminated the results of a first-in-human phase 1 trial for a novel bispecific antibody, denominated 10E8.4/iMab, demonstrating efficacy against HIV-1. The protocol was published on July 7, 2026, in the prestigious journal Nature Medicine www.nature.com .

The clinical investigation, cataloged under NCT05890963, evaluated the safety, tolerability, pharmacokinetics, and antiretroviral ramifications of the antibody in both HIV-uninfected and HIV-infected adults ctv.veeva.com . The therapeutic was administered via intravenous (IV) or subcutaneous (SC) modalities www.nature.com .

Mechanics of the Bispecific Architecture

The architecture of 10E8.4/iMab is particularly noteworthy. One component targets the CD4 receptor, analogous to Ibalizumab, which is already sanctioned for treatment-resistant HIV hivresearch.org . The second component, 10E8.4, is a broadly neutralizing antibody that neutralizes a global panel of HIV-1 pseudotyped viruses www.cavd.org . This amalgamation allows the molecule to impede viral entry through multifarious mechanisms.

This clinical milestone affords a glimpse into the future of long-acting injectable therapeutics for HIV-1. By fusing two distinct mechanisms of action, 10E8.4/iMab constitutes a formidable obstacle to viral escape.

Note on Official Social Media: No official supporting social media post from the researchers or institutions was found for this specific publication. As an alternative, readers are directed to the official publication in Nature Medicine and the ClinicalTrials.gov registry for the 10E8.4/iMab trial.